Key facts
- Analysts predict a rise in Chinese biotech deals.
- The potential easing of US trade curbs is seen as a catalyst.
- This trend could lead to a 'high tide' of M&A activity.
Market analysts anticipate a significant increase in merger and acquisition activity within China's biotechnology sector, driven by the potential easing of US trade restrictions. This outlook suggests a more favorable environment for cross-border deals and investment in Chinese biotech firms.